2 years ago

Mosaic Therapeutics Raises $28 Million in Series A to Advance Targeted Oncology Therapies

  • Mosaic Therapeutics, a UK-based oncology therapeutics company, has secured $28 million in Series A funding from Syncona Investment Management and Cambridge Innovation Capital

  • The company will use the funds to advance its pipeline of targeted oncology therapies for biomarker-stratified populations, progressing its lead programs through preclinical development to IND-enabling studies

  • Mosaic Therapeutics is a spin-out company from the Wellcome Sanger Institute, leveraging computational methods and large dataset mining to identify and develop novel targeted therapies.

      • ProblemHealthcare

      "Developing effective cancer treatments is a major challenge due to the complexity of the disease and the need for personalized approaches."

      Solution

      "Mosaic Therapeutics uses computational methods and large datasets to identify and develop novel targeted therapies for cancer, specifically focusing on biomarker-stratified populations to ensure the right treatment is given to the right patient."

      Covered on